The promise of personalized medicine has long hinged on faster, cheaper and ubiquitous availability of whole genome sequencing.
In order to make effective health care decisions to manage or fight cancer using personalized medicine strategy, oncologists ought to be able to follow the chameleonistic genome of cancer cells, and stay one step ahead by targeting strategies cancer cells employ to develop drug resistance, escape and metastasize.
